Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

KEYMAKER-U02- substudy 02B

KEYMAKER-U02- substudy 02B

18 years - 99 years
All genders
Phase 1
Patients from Penn Medicine's Abramson Cancer Center will be approached for participation.This sub-study is part of a larger research study that is testing experimental treatments for melanoma. Various study drugs will be tested in combination with pembrolizumab in this study. Treatment groups include: a) MK-7684 and pembrolizumab b) pembrolizumab alone …
Learn More

Randomized Controlled Trial of Budesonide + Surfactant

99 years or below
All genders
Phase 3
This is a randomized, masked, multicenter clinical trial with allocation to two treatment arms with early intratracheal administration of a combination of budesonide with surfactant (Intervention), as compared to surfactant alone (Control) to reduce the incidence of physiologic bronchopulmonary dysplasia (BPD) in extremely preterm infants. To be included, the infant …
Learn More
REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

REVOLUTION: Trial to Evaluate Immunotherapy Combinations with Chemotherapy for the Treatment of Patients with Previously Untreated Metastatic Pancreatic Adenocarcinoma

18 years - 99 years
All genders
Phase 1
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
Learn More
KEYMAKER-U02

KEYMAKER-U02

18 years - 99 years
All genders
Phase 1
Interventional
Patients will be recruited from within the Penn Medicine Abramson Cancer Center pool of patients. This sub-study is part of a larger research study that is testing experimental treatments for melanoma. This sub-study is testing experimental drugs when they are given before and/or after melanoma surgery. Subjects will be assigned …
Learn More
Circulating Biomarkers for Glioma

Circulating Biomarkers for Glioma

18 years - 99 years
All genders
Subjects will be recruited from the Radiation Oncology and Neurosurgery practices at the Hospital of the University of Pennsylvania. The treating radiation oncologist will determine if the patient is a potential research candidate and has the capacity to consent. The goal of this study is to collect and analyze blood …
Learn More
JK07 in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF)

JK07 in Subjects with Heart Failure with Reduced Ejection Fraction (HFrEF)

18 years - 80 years
All genders
Phase 1
Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) will be invited to participate in this study. HFrEF is a condition in which the heart pumps a lower than normal amount of blood. The purpose of this study is to evaluate the safety and activity of the investigational product in …
Learn More
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib) a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib) a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

18 years - 99 years
All genders
Phase 1
the purpose of this study is to see if lazertinib and JNJ-61186372 are safe and useful for treating patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). Eligible subjects will be those with NSCLC.
Learn More
A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)

A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)

18 years - 99 years
All genders
Phase 1
The goal of this trial is to evaluate the safety of autologous genetically modified TC-110 T cells in adult patients with aggressive NHL (DLBCL, PMBCL, TFL, MCL), high-risk indolent NHL, or ALL. And to establish the recommended phase 2 dose (RP2D) for the NHL and ALL indications according to the …
Learn More
PROACTIVE: Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

PROACTIVE: Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet

18 years - 70 years
All genders
Phase 2
Approximately 50% of patients with celiac disease have continued symptoms despite at least 12 months of treatment with a gluten free diet. PRV-015, a mAb that blocks IL-15, has been shown to reduce intestinal inflammation and improve clinical symptoms induced by gluten consumption in a previous Phase 2a gluten-challenge study …
Learn More
EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

18 years - 99 years
All genders
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
Learn More
981 - 990 of 1243